Tagged with GI

pharma With almost thirty years of experience in the life sciences sector, local Dutch consultancy firm Baggerman Farma Consult offers a wide portfolio of services to its clients in the pharmaceutical and life sciences industry to meet all of their regulatory needs. Kees Baggerman, CEO and founder, highlights the new Gateway…

Pharma Bayer broke into the top ten multinationals in Egypt this year, after achieving a remarkable 110 percent growth over the last two years. General manager Hatem Safei discusses the developments that drove this strong expansion, and the overall potential he sees in the healthcare market going forward. What are the…

Pharma The President of CEPS, the French pricing agency, reveals the issues around the launch of the hepatitis C drug Sovaldi in 2014 and of CEPS´ role to ensure that innovative products are available to all patients who are in need of them. The Sovaldi case has focused public attention on the pricing of drugs in…

pharma Jan Smeitink, CEO of Khondrion, a young biotech company designing highly innovative solutions for people suffering from mitochondrial diseases, provides an overview of the latest developments regarding the company’s lead compound and explains how its talented team and strategic partnership with the Radboud University Medical Centre will help Khondrion to…

Pharma Multinationals have struggled to adapt their Romanian strategies, but the local production sector appears to be flourishing. Much of this impetus relates directly to EU accession and the harmonization of manufacturing standards. “Initially, it was difficult to enact the transition, because the authorities handed us strict deadlines to make ourselves…

Romania Once touted by the IMS as one of the “fast followers” among the world’s “pharmerging” nations and feted by the international investor community in the wake of EU accession, Romania’s pharmaceutical industry appears resurgent once more after a number of years on the back burner. In 2014, Romania’s market size…

pharma The managing director of Southern Medical, Malan de Villiers illustrates the sheer diversity of the company’s current activities and portfolio within South Africa as a leading implant devices company, while depicting his vision on the South African medical device market. He also reveals the competitive and regulatory challenges in the…

pharma Abdon Nevares, General Manager of Ci Medical Technologies discusses the importance of teamwork, how the recent name change of the business has opened new business opportunities and how Puerto Rico can act as a gateway for expansion into the Latin American market. You became general manager of Ci Medical Technologies…

pharma Omar Muñiz, President of ShareTech Group, discusses his company’s competitive positioning as a leading engineering, architecture, environmental consulting, and construction program management firm for the Puerto Rican life sciences industry. What are the main services ShareTech offers to the clients? We offer project planning & program management, environmental consulting, architectural…

Pharma The managing director of MC Pharma Group, Henk Krebs illustrates how MC Pharma’s new operating structure enables the group to better service its clients, and also highlights the role of strategic partnerships in fueling the company’s growth ambitions both domestically and internationally. He also shares his insights on the South…

pharma Leonardo Vingiani, Director of Assobiotec, discusses how the country’s biotech industry has evolved since 2009, what areas still need improving and the enormous progress which has been made in unlocking the sector’s potential in Italy. Leonardo, to start off, what are some of the major milestones which the industry, and…

pharma The founder and managing director of LT Clinical Research, one of the first wholly black-owned South African CRO, reveals how South Africa is a very conducive environment for CROs, with a diverse patient population, a well-established regulatory framework and a currency that compares well to other African currencies; why the…